Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients.

about

Relationship between plasma protease inhibitor concentrations and lipid elevations in HIV patients on a double-boosted protease inhibitor regimen (saquinavir/lopinavir/ritonavir).

P2860

Q43185204-672F9BB7-F2AE-42A2-B7F9-B3E84181CB5E

P2860

Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients.

Item

http://www.wikidata.org/entity/Q46571253

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Pilot study of saquinavir and ...... r-naive HIV-positive patients.

@en

Pilot study of saquinavir and ...... r-naive HIV-positive patients.

@nl

type

Item

label

Pilot study of saquinavir and ...... r-naive HIV-positive patients.

@en

Pilot study of saquinavir and ...... r-naive HIV-positive patients.

@nl

prefLabel

Pilot study of saquinavir and ...... r-naive HIV-positive patients.

@en

Pilot study of saquinavir and ...... r-naive HIV-positive patients.

@nl

P1476

Pilot study of saquinavir and ...... r-naive HIV-positive patients.

@en

P2093

Abby Shevitz

http://www.w3.org/2001/XMLSchema#string

Anne Morris

http://www.w3.org/2001/XMLSchema#string

Calvin Cohen

http://www.w3.org/2001/XMLSchema#string

Clarissa Foy

http://www.w3.org/2001/XMLSchema#string

Danielle Gordon

http://www.w3.org/2001/XMLSchema#string

Erno van Schaic

http://www.w3.org/2001/XMLSchema#string

James Hellinger

http://www.w3.org/2001/XMLSchema#string

Lenore Jackson-Pope

http://www.w3.org/2001/XMLSchema#string

Sandy Sheble-Hall

http://www.w3.org/2001/XMLSchema#string

P2860

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults

Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus.

Saquinavir: a review of its use in boosted regimens for treating HIV infection.

The metabolic effects of lopinavir/ritonavir in HIV-negative men

In vitro antiviral interaction of lopinavir with other protease inhibitors.

The prevalence of antiretroviral drug resistance in the United States.

Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy.

Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy.

Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir.

P304

107-117

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1310/YGKE-7K4V-UF5R-4F1G

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15983895

http://www.w3.org/2001/XMLSchema#string

Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients.

about

P2860

P2860

Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698